» Articles » PMID: 36123679

Prevalence and Risk Factors of High Cholesterol and Triglycerides Among People with HIV in Texas

Overview
Journal AIDS Res Ther
Publisher Biomed Central
Date 2022 Sep 19
PMID 36123679
Authors
Affiliations
Soon will be listed here.
Abstract

Background: People with HIV (PWH) commonly have elevated cholesterol and triglycerides levels that have been linked to medications. However, healthy behaviors including lifestyle changes can lower high cholesterol (CHOL) or high triglycerides (TG), thereby reducing individual risk for cardiovascular diseases. This study aimed to determine the prevalence and risk factors associated with high CHOL or TG among PWH in Texas.

Methods: Cross-sectional data of 981 PWH from the 2015-2017 Texas and Houston Medical Monitoring Projects were examined. High CHOL or TG was identified by medical chart diagnosis, CHOL or TG medication use, or most recent fasting lab ≥ 200 mg/dl (total CHOL) or ≥ 150 mg/dl (TG). High CHOL or TG associations with sociodemographic and clinical characteristics were assessed using Rao-Scott chi-square tests. Prevalence of high CHOL or TG development was calculated using multivariable logistic regression model.

Results: High CHOL or TG prevalence was 41% with participants being mostly male (73%), ≥ 40 years (68%), with overweight (31%) or obesity (28%), and virally suppressed (62%). Compared with PWH < 40 years of age, PWH in their 40s, 50s, and ≥ 60s were 57%, 64%, and 62% more likely to have high CHOL or TG, respectively. Participants with overweight and obesity were 41% and 30% more likely to have high CHOL or TG than those with normal weight (BMI: 18.5- < 25), respectively.

Conclusion: Since high CHOL and TG are modifiable CVD risk factors, increased education and lifestyle modification interventions are warranted to prevent the development of high CHOL or TG among PWH.

Citing Articles

Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study.

Roux C, Mason S, du Toit L, Nel J, Rossouw T, Steel H Viruses. 2024; 16(9).

PMID: 39339938 PMC: 11437493. DOI: 10.3390/v16091462.


The Association between IL-1β and IL-18 Levels, Gut Barrier Disruption, and Monocyte Activation during Chronic Simian Immunodeficiency Virus Infection and Long-Term Suppressive Antiretroviral Therapy.

Thirugnanam S, Wang C, Zheng C, Grasperge B, Datta P, Rappaport J Int J Mol Sci. 2024; 25(16.

PMID: 39201388 PMC: 11354606. DOI: 10.3390/ijms25168702.


Epidemiology of obesity among people with HIV.

Talathi R, Anekwe C, Toribio M Curr Opin HIV AIDS. 2023; 19(1):1-5.

PMID: 37916907 PMC: 10842423. DOI: 10.1097/COH.0000000000000830.


Prevalence of Dyslipidemia and Its Determinants Among the Adult Population of the Jazan Region.

Ghazwani M, Mahmood S, Gosadi I, Bahri A, Ghazwani S, Khmees R Int J Gen Med. 2023; 16:4215-4226.

PMID: 37745134 PMC: 10516128. DOI: 10.2147/IJGM.S429462.

References
1.
Fontas E, van Leth F, Sabin C, Friis-Moller N, Rickenbach M, dArminio Monforte A . Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis. 2004; 189(6):1056-74. DOI: 10.1086/381783. View

2.
Kuklina E, Yoon P, Keenan N . Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999-2006. Ann Fam Med. 2010; 8(4):327-33. PMC: 2906527. DOI: 10.1370/afm.1137. View

3.
Worm S, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F . Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2009; 201(3):318-30. DOI: 10.1086/649897. View

4.
Rasmussen L, Mathiesen E, Kronborg G, Pedersen C, Gerstoft J, Obel N . Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS One. 2012; 7(9):e44575. PMC: 3440341. DOI: 10.1371/journal.pone.0044575. View

5.
Rader D, Hovingh G . HDL and cardiovascular disease. Lancet. 2014; 384(9943):618-625. DOI: 10.1016/S0140-6736(14)61217-4. View